- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BIBF-1120 | BIBF1120 | Ofev® | Vargatef®
nintedanib is an approved drug (FDA & EMA (2014))
Compound class: Synthetic organic
Comment: Nintedanib is a kinase inhibitor, targeting three arms of proangiogenic signalling via VEGFRs, PDGFR and FGFR . It was developed by Boehringer Ingelheim.
Marketed formulations contain nintedanib esylate (PubChem CID 135476717).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: nintedanib
|Nintedanib is active in vivo, its effects observed as decreased vessel density and integrity and significant growth inhibition . Nintedanib is rapidly metabolised to BIBF-1202 .
We have tagged FLT4 (VEGFR-3) as this drug's primary molecular target for data metrics purposes only. We fully acknowledge the multi-targeted nature of nintedanib and include reported kinase interactions in the table below.
|Selectivity at catalytic receptors|
|Key to terms and symbols||Click column headers to sort|